Developer docs
API playgroundTry for free, no card

Search company profiles

DreamCIS

Full company profile

uuid000lypd

Namestring
DreamCIS
Legal namestring
주식회사 드림씨아이에스
Websiteurl
dreamcis.com
Company typeenum
Public
Founded yearint
2000
Descriptiontext

DreamCIS is a Seoul-headquartered, KOSDAQ-listed clinical research organization (ticker 223250) founded in 2000 and operating as a strategic subsidiary of Chinese CRO Tigermed. The company provides a full-lifecycle drug development platform spanning Phase 1-4 clinical trials, non-interventional studies (NIS), registry post-marketing studies (r-PMS), and multi-regional clinical trials (MRCT), with a documented track record of 714 clinical trials, 304 NIS, and 391 r-PMS across oncology (125 trials), cardiovascular (231), endocrinology (150), and rare disease (62). Core platforms include clinical development services, Site Management Organization (SMO) operations, healthcare regulatory consulting, medical device services (CE-MDR and FDA global registration), and an organoid- and AI-based preclinical evaluation capability built through the 2025 absorption of Promedis and a $10M lead investment in Curi Bio.

The company's revenue model is predominantly B2B professional services priced via multi-year enterprise contracts on a quote basis, with revenue growing from 389 billion KRW (2022) to 666 billion KRW (FY2025), reaching 174 billion KRW in Q1 2026 (up 22.9% YoY). Customer segments are split between domestic and global pharmaceutical companies (enterprise field sales motion with named relationships including Eli Lilly, BMS, RealOne Medicines, and QingFeng) and Korean biotech companies that DreamCIS supports in clinical execution, global licensing, and investor relations (notably through the co-hosted Korea Integrated Investment & Licensing Forum with KDRA in 2026). Go-to-market is relationship-driven and targeted at biopharma decision-makers rather than broad marketing.

DreamCIS leverages parent Tigermed's global network spanning 50 countries and 29 networks to bridge Korean biotech sponsors into late-phase global trials, while pursuing inorganic growth through three sequential acquisitions: Medipen in 2022 (SMO, regulatory consulting, data management), Medipen SMO in 2024 (incorporating LSK Global PS SMO assets), and Promedis in 2025 (organoid and preclinical services). Strategic investments in Curi Bio (organoid) and Vertis (proteomics), plus ownership of the BGM0504 GLP-1/GIP dual-action obesity candidate (Phase 3 IND filed domestically), indicate an evolving strategy from pure-service CRO toward an integrated drug development and commercialization platform. Distribution is direct enterprise sales within Korea, channel-resold internationally through Tigermed.

Short descriptiontext

DreamCIS is a KOSDAQ-listed South Korean full-lifecycle clinical research organization providing Phase 1-4 trials, SMO services, regulatory consulting, and organoid-based preclinical evaluation, serving pharmaceutical companies and Korean biotech firms through parent Tigermed's 50-country global network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical research organization, clinical trial services, site management organization, regulatory consulting, organoid preclinical evaluation
Industry4 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
NAICS code1 code
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Research Organization (CRO) Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Clinical Development Services
TypeProfessional Services
Description

Core CRO services including clinical trial design, execution, monitoring, and regulatory submission support. Revenue from clinical trial service contracts with biopharma companies.

dreamcis.com
2Clinical Trial Support Services (SMO)
TypeProfessional Services
Description

Clinical site management, patient enrollment, and research conduct support through Medipen SMO. Revenue grew from 11 billion KRW in 2024 to 50 billion KRW in 2025, with 191.5% YoY growth in Q1 2026.

dreamcis.com
3Consulting Services
TypeProfessional Services
Description

Healthcare regulatory consulting, medical writing, data management, and statistical services through Medipen subsidiary.

dreamcis.com
4Strategic Investments
TypeLicensing Royalties
Description

Investment returns from leading Series B rounds in biotech companies like Curi Bio, generating potential capital gains and strategic partnerships.

pulse2.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom enterprise contracts based on trial scope and complexity
ModelOtherBilling cadenceMulti-year contract
Notes

Clinical development services priced based on trial phase, therapeutic area, number of sites, patient enrollment targets, and regulatory requirements. No public pricing available; direct inquiry required.

dreamcis.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

DreamCIS is a full-lifecycle clinical research organization (CRO) providing clinical trial design, execution, monitoring, and regulatory submission support across oncology, cardiovascular, endocrinology, and rare diseases. Through subsidiaries Medipen and Medipen SMO, the company delivers site management, patient enrollment, medical writing, data management, statistics, and healthcare regulatory consulting including IND and advanced therapy strategies. Promedice (acquired 2025) adds organoid-based preclinical evaluation and AI-driven drug development, while parent Tigermed's 50-country network enables multi-regional clinical trials (MRCTs) for Korean biotech and global pharma sponsors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Achieved #1 domestic CRO revenue position in 2025 (connected basis)
+2 more records
Product overview1 text field

DreamCIS operates as a full-lifecycle clinical development platform, evolving beyond traditional CRO services to offer integrated clinical development, regulatory consulting, and preclinical evaluation solutions. The core offering includes Clinical Development Services spanning Phase 1-4 trials, IIT, PMS, and medical device studies, supported by MediPinn SMO services acquired in 2022. Healthcare Regulatory Consulting provides IND preparation, regulatory strategy, and advanced therapy development support including cell therapy, gene therapy, and microbiome-based products. Strategic investments in organoid technology through Curi Bio and the BGM0504 obesity treatment pipeline represent new growth engines. The company leverages parent Tigermed's global network across 50 countries to connect domestic clinical trials to international markets.

Product and service5 records
1Clinical Development Services
CategoryClinical Research Organization Services
Description

Full-service CRO offering clinical trial design, execution, monitoring, and management across multiple therapeutic areas including oncology, cardiovascular, endocrinology, and rare diseases. Covers Phase 1-4 trials, IIT, PMS, NIS, and r-PMS studies for domestic and global pharmaceutical sponsors.

2Medipen SMO Services
CategorySite Management Organization Services
Description

Site Management Organization services providing clinical trial site support, investigator coordination, and patient enrollment assistance. Delivered via Medipen (acquired 2022) and Medipen SMO (established 2024 with LSK Global PS SMO business rights); revenue grew from 11B KRW (2024) to 50B KRW (2025) with 191.5% YoY Q1 2026 growth.

3Medical Device Services
CategoryRegulatory & Clinical Consulting
Description

Clinical development and regulatory consulting services for medical devices, supporting CE-MDR and FDA global registration strategies for medical device manufacturers entering or expanding in regulated markets.

4Healthcare Regulatory Consulting
CategoryRegulatory & Clinical Consulting
Description

Comprehensive regulatory affairs support including IND preparation, drug approval strategy, clinical trial planning, medical writing, data management, and statistics. Includes advanced therapy product development consulting for cell therapy, gene therapy, and microbiome-based products.

5Organoid Preclinical Evaluation Services (Promedice)
CategoryPreclinical Drug Development Services
Description

Organoid and AI-based preclinical evaluation services for drug discovery prediction, delivered through subsidiary Promedice (absorbed 2025). Supports the integrated preclinical-to-clinical value chain with engineered-tissue and high-resolution analytics across cardiac, skeletal muscle, neuromuscular, metabolic, and smooth muscle tissue applications.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Acquired in 2022, Medipen provides SMO services, Medical Writing, Data Management (DM), Statistics, and healthcare regulatory consulting. The acquisition expanded DreamCIS's business scope from traditional CRO into comprehensive clinical support services.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-hosting the 2026 Korea Integrated Investment & Licensing Forum with KDRA. The forum brings together global pharma (Eli Lilly, BMS), investment firms (Temasek-Tigermed, B Capital, CMBI), and Korean biotech companies for investment and licensing discussions.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Johns Hopkins University hosts the Global Biotechnology Innovation Summit in Songdo, Incheon. DreamCIS presenting alongside Samsung Biologics and Celltrion as industry leaders. Forum covers organoids, AI-based drug development, biomanufacturing, and investment strategies.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Parent company providing access to global clinical trial network spanning 50 countries. DreamCIS leverages Tigermed's 29-country, 50-network infrastructure to connect domestic Phase 1 trials to late-phase global trials for Korean biotech companies and serve as a bridge for international pharma.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

DreamCIS acquired LSK Global PS's SMO business rights in 2024, strengthening its clinical site management capabilities through Medipen SMO subsidiary.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Absorbed via merger in 2024, Promedis is an organoid and preclinical evaluation company. The acquisition supports DreamCIS's strategy to build integrated preclinical-to-clinical value chain with AI and organoid-based platforms.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global #1 CRO with extensive Korean operations spanning clinical, real-world evidence, and technology-enabled trial services. Comparable on full-lifecycle clinical development but at vastly larger scale and broader therapeutic coverage than DreamCIS.

TypeDirect peer
Description

Mid-sized, clinical-focused CRO with strong biotech customer base and full-service Phase 1-4 capabilities. Closely comparable business model — focused on clinical development services — though Medpace is larger and operates primarily in US/EU.

TypeBroad incumbent
Description

China-based global CRO/CDMO offering preclinical, clinical, and biologics services. Comparable on Asia-rooted full-lifecycle drug development, but WuXi has much broader scale, US/EU sites, and ongoing US legislative (BIOSECURE) headwinds.

TypeDirect peer
Description

Chinese-listed parent company and the largest clinical CRO in China, providing the 50-country global network DreamCIS leverages. Operates overlapping Phase 1-4 clinical trial services and serves as both supplier (referrals) and structural benchmark for valuation and capability comparison.

TypeBroad incumbent
Description

Global clinical CRO (post-PRA Health merger) with strong Asia-Pacific footprint including Korea. Overlaps with DreamCIS on Phase 1-4 trial execution, biotech/sponsor services, and lab services, but at substantially greater scale.

TypeBroad incumbent
Description

Global clinical CRO spun out of Labcorp in 2023, with Korean operations covering Phase 1-4 trials, biostatistics, and regulatory services. Direct overlap on clinical CRO services but with broader therapeutic area coverage and global scale.

TypeBroad incumbent
Description

Global mid-to-large clinical CRO with Korean operations covering Phase 1-4 trials, biopharma services, and regulatory consulting. Comparable full-lifecycle platform but with deeper therapeutic specialization and global sponsor relationships than DreamCIS.

TypeDirect peer
Description

China-based CRO/CDMO with growing Korean and global clinical operations, covering preclinical through clinical services. Comparable integrated preclinical-to-clinical platform positioning, though Pharmaron has substantially larger preclinical/CMC scale.

TypeDirect peer
Description

Korean-headquartered clinical CRO offering Phase 1-4 trial services, SMO, and biostatistics across the same therapeutic areas (oncology, cardiovascular, endocrinology). Direct domestic competitor — DreamCIS even acquired LSK Global PS's SMO business rights in 2024, underscoring the close overlap.

TypeEmerging player
Description

US-based preclinical platform using engineered tissue and organoid analytics for drug discovery. Strategic investee of DreamCIS ($10M Series B lead, Dec 2025) and integrated into DreamCIS's preclinical value chain via the Promedis subsidiary.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DreamCIS

Clinical Research Organization (CRO) Servicesdreamcis.com

DreamCIS is a KOSDAQ-listed South Korean full-lifecycle clinical research organization providing Phase 1-4 trials, SMO services, regulatory consulting, and organoid-based preclinical evaluation, serving pharmaceutical companies and Korean biotech firms through parent Tigermed's 50-country global network.

What DreamCIS does

DreamCIS is a Seoul-headquartered, KOSDAQ-listed clinical research organization (ticker 223250) founded in 2000 and operating as a strategic subsidiary of Chinese CRO Tigermed. The company provides a full-lifecycle drug development platform spanning Phase 1-4 clinical trials, non-interventional studies (NIS), registry post-marketing studies (r-PMS), and multi-regional clinical trials (MRCT), with a documented track record of 714 clinical trials, 304 NIS, and 391 r-PMS across oncology (125 trials), cardiovascular (231), endocrinology (150), and rare disease (62). Core platforms include clinical development services, Site Management Organization (SMO) operations, healthcare regulatory consulting, medical device services (CE-MDR and FDA global registration), and an organoid- and AI-based preclinical evaluation capability built through the 2025 absorption of Promedis and a $10M lead investment in Curi Bio.

The company's revenue model is predominantly B2B professional services priced via multi-year enterprise contracts on a quote basis, with revenue growing from 389 billion KRW (2022) to 666 billion KRW (FY2025), reaching 174 billion KRW in Q1 2026 (up 22.9% YoY). Customer segments are split between domestic and global pharmaceutical companies (enterprise field sales motion with named relationships including Eli Lilly, BMS, RealOne Medicines, and QingFeng) and Korean biotech companies that DreamCIS supports in clinical execution, global licensing, and investor relations (notably through the co-hosted Korea Integrated Investment & Licensing Forum with KDRA in 2026). Go-to-market is relationship-driven and targeted at biopharma decision-makers rather than broad marketing.

DreamCIS leverages parent Tigermed's global network spanning 50 countries and 29 networks to bridge Korean biotech sponsors into late-phase global trials, while pursuing inorganic growth through three sequential acquisitions: Medipen in 2022 (SMO, regulatory consulting, data management), Medipen SMO in 2024 (incorporating LSK Global PS SMO assets), and Promedis in 2025 (organoid and preclinical services). Strategic investments in Curi Bio (organoid) and Vertis (proteomics), plus ownership of the BGM0504 GLP-1/GIP dual-action obesity candidate (Phase 3 IND filed domestically), indicate an evolving strategy from pure-service CRO toward an integrated drug development and commercialization platform. Distribution is direct enterprise sales within Korea, channel-resold internationally through Tigermed.

DreamCIS firmographics

Firmographics
Name
DreamCIS
Legal name
주식회사 드림씨아이에스
Website
https://dreamcis.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
101–250 employees
Short description
DreamCIS is a KOSDAQ-listed South Korean full-lifecycle clinical research organization providing Phase 1-4 trials, SMO services, regulatory consulting, and organoid-based preclinical evaluation, serving pharmaceutical companies and Korean biotech firms through parent Tigermed's 50-country global network.
Ownership category
akta.pro rank

DreamCIS industry classification

Industry
Product category
Clinical Research Organization (CRO) Services
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs

Keywords

  • Clinical research organization
  • Clinical trial services
  • Site management organization
  • Regulatory consulting
  • Organoid preclinical evaluation

Where DreamCIS is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

DreamCIS business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Development Services: Core CRO services including clinical trial design, execution, monitoring, and regulatory submission support. Revenue from clinical trial service contracts with biopharma companies.
  2. Clinical Trial Support Services (SMO): Clinical site management, patient enrollment, and research conduct support through Medipen SMO. Revenue grew from 11 billion KRW in 2024 to 50 billion KRW in 2025, with 191.5% YoY growth in Q1 2026.
  3. Consulting Services: Healthcare regulatory consulting, medical writing, data management, and statistical services through Medipen subsidiary.
  4. Strategic Investments: Investment returns from leading Series B rounds in biotech companies like Curi Bio, generating potential capital gains and strategic partnerships.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom enterprise contracts based on trial scope and complexity

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

DreamCIS product offering

Product offering

Core offering

DreamCIS is a full-lifecycle clinical research organization (CRO) providing clinical trial design, execution, monitoring, and regulatory submission support across oncology, cardiovascular, endocrinology, and rare diseases. Through subsidiaries Medipen and Medipen SMO, the company delivers site management, patient enrollment, medical writing, data management, statistics, and healthcare regulatory consulting including IND and advanced therapy strategies. Promedice (acquired 2025) adds organoid-based preclinical evaluation and AI-driven drug development, while parent Tigermed's 50-country network enables multi-regional clinical trials (MRCTs) for Korean biotech and global pharma sponsors.

Product overview

DreamCIS operates as a full-lifecycle clinical development platform, evolving beyond traditional CRO services to offer integrated clinical development, regulatory consulting, and preclinical evaluation solutions. The core offering includes Clinical Development Services spanning Phase 1-4 trials, IIT, PMS, and medical device studies, supported by MediPinn SMO services acquired in 2022. Healthcare Regulatory Consulting provides IND preparation, regulatory strategy, and advanced therapy development support including cell therapy, gene therapy, and microbiome-based products. Strategic investments in organoid technology through Curi Bio and the BGM0504 obesity treatment pipeline represent new growth engines. The company leverages parent Tigermed's global network across 50 countries to connect domestic clinical trials to international markets.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Development Services Full-service CRO offering clinical trial design, execution, monitoring, and management across multiple therapeutic areas including oncology, cardiovascular, endocrinology, and rare diseases. Covers Phase 1-4 trials, IIT, PMS, NIS, and r-PMS studies for domestic and global pharmaceutical sponsors.
  • Medipen SMO Services Site Management Organization services providing clinical trial site support, investigator coordination, and patient enrollment assistance. Delivered via Medipen (acquired 2022) and Medipen SMO (established 2024 with LSK Global PS SMO business rights); revenue grew from 11B KRW (2024) to 50B KRW (2025) with 191.5% YoY Q1 2026 growth.
  • Medical Device Services Clinical development and regulatory consulting services for medical devices, supporting CE-MDR and FDA global registration strategies for medical device manufacturers entering or expanding in regulated markets.
  • Healthcare Regulatory Consulting Comprehensive regulatory affairs support including IND preparation, drug approval strategy, clinical trial planning, medical writing, data management, and statistics. Includes advanced therapy product development consulting for cell therapy, gene therapy, and microbiome-based products.
  • Organoid Preclinical Evaluation Services (Promedice) Organoid and AI-based preclinical evaluation services for drug discovery prediction, delivered through subsidiary Promedice (absorbed 2025). Supports the integrated preclinical-to-clinical value chain with engineered-tissue and high-resolution analytics across cardiac, skeletal muscle, neuromuscular, metabolic, and smooth muscle tissue applications.

Quantifiable outcome

  • Achieved #1 domestic CRO revenue position in 2025 (connected basis)
  • +2 more outcomes

Companies that use DreamCIS

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

DreamCIS technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

DreamCIS partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and flagship.

  • MedipencoreStrategic or Co-development Partner · 1 January 2022Acquired in 2022, Medipen provides SMO services, Medical Writing, Data Management (DM), Statistics, and healthcare regulatory consulting. The acquisition expanded DreamCIS's business scope from traditional CRO into comprehensive clinical support services.
  • KDRA (Korean Drug Developers Association)coreStrategic or Co-development PartnerCo-hosting the 2026 Korea Integrated Investment & Licensing Forum with KDRA. The forum brings together global pharma (Eli Lilly, BMS), investment firms (Temasek-Tigermed, B Capital, CMBI), and Korean biotech companies for investment and licensing discussions.
  • Johns Hopkins UniversityflagshipStrategic or Co-development PartnerJohns Hopkins University hosts the Global Biotechnology Innovation Summit in Songdo, Incheon. DreamCIS presenting alongside Samsung Biologics and Celltrion as industry leaders. Forum covers organoids, AI-based drug development, biomanufacturing, and investment strategies.
  • TigermedflagshipStrategic or Co-development PartnerParent company providing access to global clinical trial network spanning 50 countries. DreamCIS leverages Tigermed's 29-country, 50-network infrastructure to connect domestic Phase 1 trials to late-phase global trials for Korean biotech companies and serve as a bridge for international pharma.
  • LSK Global PScoreStrategic or Co-development PartnerDreamCIS acquired LSK Global PS's SMO business rights in 2024, strengthening its clinical site management capabilities through Medipen SMO subsidiary.
  • PromediscoreStrategic or Co-development PartnerAbsorbed via merger in 2024, Promedis is an organoid and preclinical evaluation company. The acquisition supports DreamCIS's strategy to build integrated preclinical-to-clinical value chain with AI and organoid-based platforms.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

DreamCIS competitors and assessment

Company assessment

Broad incumbents

  • IQVIA: Global #1 CRO with extensive Korean operations spanning clinical, real-world evidence, and technology-enabled trial services. Comparable on full-lifecycle clinical development but at vastly larger scale and broader therapeutic coverage than DreamCIS.
  • WuXi AppTec: China-based global CRO/CDMO offering preclinical, clinical, and biologics services. Comparable on Asia-rooted full-lifecycle drug development, but WuXi has much broader scale, US/EU sites, and ongoing US legislative (BIOSECURE) headwinds.
  • ICON plc: Global clinical CRO (post-PRA Health merger) with strong Asia-Pacific footprint including Korea. Overlaps with DreamCIS on Phase 1-4 trial execution, biotech/sponsor services, and lab services, but at substantially greater scale.
  • Fortrea (Labcorp Drug Development spinoff): Global clinical CRO spun out of Labcorp in 2023, with Korean operations covering Phase 1-4 trials, biostatistics, and regulatory services. Direct overlap on clinical CRO services but with broader therapeutic area coverage and global scale.
  • Parexel: Global mid-to-large clinical CRO with Korean operations covering Phase 1-4 trials, biopharma services, and regulatory consulting. Comparable full-lifecycle platform but with deeper therapeutic specialization and global sponsor relationships than DreamCIS.

Direct peers

  • Medpace: Mid-sized, clinical-focused CRO with strong biotech customer base and full-service Phase 1-4 capabilities. Closely comparable business model — focused on clinical development services — though Medpace is larger and operates primarily in US/EU.
  • Tigermed: Chinese-listed parent company and the largest clinical CRO in China, providing the 50-country global network DreamCIS leverages. Operates overlapping Phase 1-4 clinical trial services and serves as both supplier (referrals) and structural benchmark for valuation and capability comparison.
  • Pharmaron: China-based CRO/CDMO with growing Korean and global clinical operations, covering preclinical through clinical services. Comparable integrated preclinical-to-clinical platform positioning, though Pharmaron has substantially larger preclinical/CMC scale.
  • LSK Global PS: Korean-headquartered clinical CRO offering Phase 1-4 trial services, SMO, and biostatistics across the same therapeutic areas (oncology, cardiovascular, endocrinology). Direct domestic competitor — DreamCIS even acquired LSK Global PS's SMO business rights in 2024, underscoring the close overlap.

Emerging players

  • Curi Bio: US-based preclinical platform using engineered tissue and organoid analytics for drug discovery. Strategic investee of DreamCIS ($10M Series B lead, Dec 2025) and integrated into DreamCIS's preclinical value chain via the Promedis subsidiary.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

DreamCIS social profiles

Digital presence

DreamCIS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DreamCIS leadership team

Management profile

Number of profiles

Profiles1 record

DreamCIS subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

DreamCIS funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DreamCIS M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DreamCIS

What does DreamCIS do?

DreamCIS is a full-lifecycle clinical research organization (CRO) providing clinical trial design, execution, monitoring, and regulatory submission support across oncology, cardiovascular, endocrinology, and rare diseases. Through subsidiaries Medipen and Medipen SMO, the company delivers site management, patient enrollment, medical writing, data management, statistics, and healthcare regulatory consulting including IND and advanced therapy strategies. Promedice (acquired 2025) adds organoid-based preclinical evaluation and AI-driven drug development, while parent Tigermed's 50-country network enables multi-regional clinical trials (MRCTs) for Korean biotech and global pharma sponsors.

Is DreamCIS a public or private company?

DreamCIS is a public company. It is classified as public and is currently operating.

When was DreamCIS founded?

DreamCIS was founded in 2000. It employs 101 to 250 people.

Where is DreamCIS based?

DreamCIS is headquartered in Seoul, South Korea, in the Asia region.

How does DreamCIS make money?

Four revenue lines are on record. Clinical Development Services are the primary driver. The others are clinical Trial Support Services (SMO), consulting Services and strategic Investments.

Who are DreamCIS's main competitors?

Broad incumbents on record are IQVIA, WuXi AppTec, ICON plc, Fortrea (Labcorp Drug Development spinoff) and Parexel. Direct peers are Medpace, Tigermed, Pharmaron and LSK Global PS. Curi Bio is listed as an emerging player.

Does DreamCIS have an API?

No public API is recorded for DreamCIS.

What industry is DreamCIS in?

DreamCIS's product category is Clinical Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals